to transplantation, such as uveitis [5], rheumatoid arthriallografts.
tionship between this drug and the microangiopathic and thrombotic microangiopathy (TMA) in renal allografts is process. It is noteworthy that only a minority of the well documented. However, predisposing factors and therapy patients with CsA-associated TMA have the full clinical guidelines are not adequately characterized.
Methods. We reviewed 188 patients with kidney or kidneypicture of hemolytic uremic syndrome [9] and that the pancreas transplants who were treated between January 1994 diagnosis is frequently not apparent before the renal and December 1996 with prednisone, CsA, or tacrolimus, and biopsy is performed. ing from CsA to tacrolimus, with good graft function in 81% of the recipients one year after the TMA episode.
Organ Transplantation Program during a three-year pebrin thrombi were observed in arterioles or glomerular capillaries [3, 11, 17] . Although vascular changes diagriod, between January 1, 1994, and December 31, 1996 . One hundred forty-nine patients were transplanted with nostic of severe acute rejection predominate in muscular vessels, arterioles and glomeruli may become involved kidney only. Thirty-eight patients simultaneously received kidney and pancreas allografts, and one patient in severe or accelerated rejection [18, 19] . Acute rejection was graded using the Banff criteria [16, 20] . Chronic had sequential kidney and pancreas grafts. During the three-year period, 19 patients never had renal graft dystransplant nephropathy was graded based on the severity of interstitial fibrosis and tubular atrophy [16, 20] . function and were not biopsied. The other 169 recipients had a total of 396 renal graft biopsies for the diagnosis Statistical analysis of renal graft dysfunction, and the number of biopsies per patient varied from one to seven. Renal graft dysfunction Statistical comparisons were made using chi-square analysis with Yates' correction or Student's unpaired was defined as a rise in serum creatinine (S Cr ) of 0.5 mg/ dl or greater above baseline.
t-test where appropriate, using GraphPad Prism 2.01 (StatMate) for Windows 95 (GraphPad Software Inc., Therapy San Diego, CA, USA). Therapy during the three-year period included in this study consisted of CsA or tacrolimus (Prograf; Fujisawa-RESULTS USA, Deerfield, IL, USA); azathioprine, or mycophenoClinical data late mofetil (CellCept; Roche, Nutley, NJ, USA), and prednisone. CsA was initially started at 10 mg/kg dose
The clinical data of the 188 recipients are shown in Table 1 . All patients included in this study had negative and was later titrated according to trough blood levels and maintenance dose in the range of 5 to 8 mg/kg. serology for hepatitis C. TMA was observed in 26 of the 188 renal allograft recipients (that is, 14%) and in 26 of Blood levels were measured by high-performance liquid chromatography (HPLC). CsA was used in two forms: the total of 169 patients who had a renal graft biopsy (that is, 15%). Of the 162 renal graft recipients who did Sandimmune (Novartis, Summit, NJ, USA) and the microemulsion form, Neoral (Novartis). When Neoral not have TMA, 116 (72%) had functioning grafts with a mean S Cr of 2.43 Ϯ 0.8 mg/dl at the end of the threebecame available, new patients were placed on this form of therapy, and some of the patients who had been on year study period.
Patients with TMA did not differ significantly with the older preparation (Sandimmune) were converted, depending on the primary physician's preference.
respect to age, sex, race, living-related vs. cadaveric donor status, and human lymphocyte antigen match status We routinely used a dihydropyridine calcium channel blocker for the treatment of post-transplantation hyperfrom the recipients with no TMA. Although more male and African American patients were transplanted during tension, occasionally with the addition of a loop diuretic. We did not use prophylactic induction therapy with eithe index period, TMA appeared to be more frequent in female and in Caucasian recipients; however, the difther antithymocyte globulin or murine anti-CD3 antibodies (OKT3; Orthoclone, West Orange, NJ, USA).
ference was not statistically significant. Furthermore, cytomegalovirus (CMV) mismatch was not increased in However, these agents were used when renal graft dysfunction was shown by kidney biopsy to be due to an the TMA patients, as shown in Table 1 . TMA was observed in 7 of the 39 recipients (18%) of simultaneous acute rejection of a moderate or severe grade according to the Banff classification [16] .
kidney and pancreas grafts, and in 19 of 149 patients (13%) who received a kidney-only graft. The difference Renal allograft biopsies is not statistically significant. The allograft was from a living-related donor in 27 All biopsies were studied by light microscopy. At our institution, unless clinically indicated, immunohistocases: (a) Eight of the living-related graft recipients experienced no renal graft dysfunction and represented 42% chemistry and electron microscopy are not performed routinely in renal graft biopsies. For this study, all slides of the 19 patients in the group of patients with wellfunctioning grafts who did not necessitate a biopsy. (b) were reviewed by the same pathologist (S.M.S.). Findings in glomeruli, tubules, interstitium, arterioles, and muscuEleven living-related kidney recipients had episodes of renal graft dysfunction other than TMA. (c) Eight livinglar arteries were graded using a semiquantitative method: absent (0), mild (ϩ), moderate (ϩϩ), and severe related graft recipients had TMA, corresponding to 31% of the 26 patients with TMA. The differences are not (ϩϩϩ). We routinely obtained a total of 10 slides per transplant biopsy, and stained five with hematoxylin and statistically significant and are consistent with the interpretation that living-related status did not confer proteceosin, three with periodic acid-Schiff, and two with trichrome.
tion against renal graft dysfunction. The incidence of post-transplantation urinary tract inThrombotic microangiopathy was diagnosed when fi- The diagnosis of TMA was made by graft biopsy in For our study, three groups of patients were selected.
all the 26 patients. At the time point of the diagnosis of (a) Patients with TMA. All 26 patients who had a TMA, 2 patients were on tacrolimus and 24 patients diagnosis of TMA by kidney allograft biopsy during the were on CsA. Of the 24 patients on CsA, 5 were on index period were included in this study. These 26 paSandimmune, and 19 were on the microemulsion form, Neoral. Ten patients had started with Neoral dosage tients had a total of 79 biopsies for renal graft dysfuncform, and an additional nine patients were converted tion, that is, a rise in S Cr of 0.5 mg/dl or greater above from Sandimmune to Neoral. The difference between baseline. A total of 30 renal graft biopsies was obtained the number of TMA patients on Neoral and of patients for renal graft dysfunction at time points prior to the with no renal graft dysfunction on Neoral is statistically diagnosis of TMA; 38 renal graft biopsies showed TMA, significant ( 2 ϭ 9.09, P ϭ 0.0026) and is shown in and 11 biopsies were obtained for renal graft dysfunction Figure 1 . No significant difference was observed between at time points after the diagnosis of TMA had been the number of patients on Neoral when TMA patients made.
are compared with patients with renal graft dysfunction (b) Biopsy control patients. The biopsy control group of other causes. All but two patients were on a longincluded 24 recipients who had several graft biopsies for acting dihydropyridine calcium channel blocker (nifediepisodes of renal graft dysfunction (a rise in S Cr of 0.5 pine or amlodipine). mg/dl or greater above baseline) secondary to causes Of the 26 patients, only 2 had systemic signs of TMA, different from TMA. Patients in this group were selected that is, thrombocytopenia, evidence of intravascular hefrom a total of 169 patients who had a kidney biopsy for molysis in peripheral smear, and elevated lactate dehyrenal graft dysfunction when one of the biopsies was drogenase (LDH) levels. These two patients were on obtained within one week of the biopsy from a patient Neoral when the diagnosis of TMA was made. They with TMA, and the non-TMA patient had a comparable were treated with plasmapheresis and high-dose steroids, degree of renal graft dysfunction. These 24 patients had followed by successful resolution and preservation of a total of 67 renal biopsies.
the graft in one. In the other patient, despite extensive (c) No-biopsy control patients. The no-dysfunction pheresis, the microangiopathic process did not abate uncontrol group included 19 recipients who did not have til after transplant nephrectomy. episodes of renal graft dysfunction and who never re-
The time point of the diagnosis of TMA was highly variable, between 4 and 2190 days post-transplantation. quired a renal graft biopsy.
The other statistically significant findings in biopsies with TMA, shown in Table 2 , included occlusive concentric edematous proliferation of the cells of the arteriolar walls in 34 of 38 (89%) and epithelial crescents in 9 of 38 biopsies (24%). Cellular crescents involved less than 10% of the glomeruli in most biopsies. Conversely, biopsies from the patient with three different episodes of TMA showed crescents in 38 and 30% of the glomeruli in the biopsies obtained during the second and third episodes, respectively. Immunoglobulins were not detected by immunofluorescent histochemistry. It is noteworthy that only three of the 38 biopsies with TMA showed moderate or severe rejection. (b) In the 30 biopsies taken for renal graft dysfunction episodes prior to the diagnosis of TMA, moderate or severe rejection was present in nine (30%). Isometric vacuolization of the cytoplasm of the tubular epithelium, considered a sign of acute CsA toxicity, was observed in four (13%). Eighteen of the biopsies performed for renal graft dysfunction episodes occurring prior to the diagnosis of TMA were obtained during the first 90 post-transplantation days. Interstitial fibrosis and tubular atrophy were not ob- of 11 (73%), and arteriolar hyalinization in 6 of 11 (55%).
Of the 19 renal graft recipients who did not have episodes of graft dysfunction, 1 was on tacrolimus and 18 were on CsA, 13 of whom Isometric vacuolization of the tubular epithelium was were on Sandimmune and 5 were on Neoral. The difference between not seen in any of these biopsies. column 1 and 3 is statistically significant (chi-square ϭ 9.09, P ϭ 0.0026).
Upon the diagnosis of TMA, one of the following three therapeutic interventions was implemented: conversion of CsA to tacrolimus, reduction of CsA or tacrolimus dose, discontinuation of CsA or tacrolimus. There Fourteen patients (12 of 14 on Neoral) were in their first post-transplantation year, and 12 patients (7 of 12 had were no predetermined protocol interventions; in each case, the decision to change therapy was made by the been converted to Neoral) were beyond that time point. A single episode of TMA was seen in 24 recipients; one nephrologist responsible for the care of the patient. The treatment strategies selected after the diagnosis patient had two episodes and another three, separated by time periods of over 60 days. None of the TMA of TMA are shown for all our patients in Table 3 . In 16 patients, CsA was replaced by tacrolimus (papatients had been transplanted for previous hemolytic uremic syndrome. tients one to 16; Table 3 ). The formulation was 0.5 to 1.0 mg/kg, to maintain a blood level of 5 to 12 ng/ml; a The 79 biopsies obtained from the 26 patients with TMA are subdivided as follows: 30 biopsies from 17 level of 10 to 20 ng/ml is generally considered to be the therapeutic range for this drug, especially during the patients, taken during episodes of renal graft dysfunction (S Cr between 1.4 and 9.8 mg/dl, average 3.2 mg/dl) prior first year after transplantation. Only 3 of the 16 patients (shown as 14 to 16 on Table 3 ) had to be placed on to the onset of TMA; 38 biopsies diagnostic of TMA from 26 patients (S Cr between 1.9 and 6.8 mg/dl, average dialysis 15 to 180 days after the TMA diagnosis. Renal grafts were functioning well within one year of the TMA 4.3 mg/dl); and 11 biopsies from 11 patients taken for episodes of renal graft dysfunction (S Cr between 2.4 and episode in 13 of 16 (81%) patients in whom CsA was replaced by tacrolimus. Furthermore, 11 patients had 9.4 mg/dl, average 5.6 mg/dl) occurring after the diagnosis of TMA. The following findings were observed in functioning grafts upon their most recent check-up, between 1.7-and 6.2-years post-transplantation, with a S Cr these biopsies: (a) The diagnosis of TMA was made when fibrin thrombi, as illustrated in Figure 2 , were obof between 1.1 and 2.9 mg/dl (average 2.02 Ϯ 0.17).
A further eight patients, 17 through 24 in Table 3 , served. The thrombi were localized in arterioles in 29 of 38 biopsies (76%) and/or in glomeruli in 20 of 38 (53%).
were on CsA when the diagnosis of TMA was made on 
Comment: All biopsies were performed for graft dysfunction, that is, when there was a rise in S Cr of 0.5 mg/dl or greater above baseline. Abbreviations are: TMA, thrombotic microangiopathy; Tx, transplantation.
a Result is significant when compared to biopsy from patients with no TMA (P Ͻ 0.0001) the renal graft biopsy. The CsA was discontinued in other patient had been switched to tacrolimus because of the development of acute rejection while having high three patients, and the dose was reduced in five patients. Table 3 shows that in two patients (20 and 24) , OKT3 therapeutic levels of CsA. In this patient, tacrolimus was terminated with a successful resolution of TMA. was added to the regimen.
Two patients, 25 and 26 in Table 3 , were on tacrolimus Unfortunately, this patient developed late-acute rejection 18 months later (40th month post-transplantation) at the time point when the biopsies showed TMA. We did not attempt a conversion to CsA in these two patients; in and died from opportunistic infection while receiving high-dose steroids. one patient, a simple dose reduction sufficed, and the Abbreviations are: b, African American; CTN, chronic transplant nephropathy; cong, congenital; crsc, crescentic; crt, cadaveric renal transplant; CsA, chclosporine; dial, dialysis; discnt, discontinued; dm, diabetes mellitus; esrd, end-stage renal disease; f, female; fsgs, focal segmental glomerular sclerosis; gn, glomerulonephritis; htn, hypertension; hypol, hypoplasia, iddm, insulin-dependent diabetes mellitus; infect, infection; lrd, living related donor; m, male; malf, malformation; nephct, nephrectomy; nephr, nephrotic; pyelo, pyelonephritis; recur, recurrent; S Cr , serum creatinine; syndr, syndrome; T, tacrolimus; Tx, transplant; uti, urinary tract infection; w, Caucasian.
Of the total of 26 patients with TMA, 21 (81%) had tacrolimus in 5 and CsA in 19: Neoral in 17, Sandimmune in 2, as shown in Figure 1 . All but four patients were on functioning grafts with a mean serum creatinine of 1.78 Ϯ 0.13 mg/dl at the end of one year after the diagnosis of dihydropyridine calcium channel blocker. Graft function loss was observed in 8 of the 24 patients. TMA. At the last follow-up, at 3.01 Ϯ 0.35 years, 18 of 26 (69%) patients had functioning grafts, with a mean Table 2 shows the findings in the 67 renal graft biopsies from the 24 patients with renal graft dysfunction caused serum creatinine of 1.89 Ϯ 0.14 mg/dl.
by causes other than TMA. Arteriolar changes were less Findings in patients without frequent in this group than in patients with previous thrombotic microangiopathy episodes of TMA; cellular proliferation was seen in 26 of 67 (39%) and hyalinization in 8 of 67 (12%). The Clinical and pathological data from the 26 patients with TMA were compared with clinical and pathological analysis of the 33 biopsies obtained during the first 90-days post-transplantation showed foci of interstitial fifindings in 24 patients with renal graft dysfunction caused by other causes and to the clinical data of 19 patients brosis and tubular atrophy in seven (21%), and moderate or severe rejection in seven (21%). with no renal graft dysfunction.
The therapy in the 24 patients with biopsy-proven Of the 19 patients who never had an episode of renal graft dysfunction, all but three were on a dihydropyridine renal graft dysfunction of non-TMA etiology included calcium channel blocker. One patient was on tacrolimus, when fibrin thrombi are observed in glomeruli and/or arterioles [10, 17, 24] . The nonspecific fuchsinophilia of 13 on Sandimmune, and 5 on Neoral, as shown in Figure 1 . All of these patients had an uneventful postproteins on Masson's trichrome facilitates the visualization of the fibrin thrombus, as shown in Figure 2 . Contransplantation course and never required a graft biopsy. The S Cr was between 1.1 and 2.4 mg/dl (average of 1.53 Ϯ firmation can be obtained by immunohistochemistry using antisera to fibrin. The diagnosis is evident when a 0.11), up to 67 months after transplantation (average 3.2 Ϯ 0.4 years).
large number of thrombi are present, but in cases with scarce thrombi, careful scrutiny of all the sections is essential in order to make the diagnosis. A statistically DISCUSSION significant finding in this series is the presence of cellular Although the association between TMA and CsA is crescents in biopsies with TMA, as compared with biopwell established, medical literature on CsA-associated sies from renal grafts with dysfunction of other etiology TMA in renal allografts is not abundant. Our review (Table 2 ). In the biopsies with crescents, antibasement demonstrated only three studies based on a series of membrane disease and antineutrophil cytoplasmic antimore than 10 patients [7, 21, 22] . Our series of 26 renal body-associated glomerulonephritis were ruled out by graft recipients with TMA-24 patients with CsA-associserology, and immunoglobulin deposition was not obated TMA-possibly constitutes the largest study pubserved in the glomeruli. It is noteworthy that in older lished to date. CsA-associated TMA is not exclusive to medical literature, crescents are included among the glorenal allografts. The medical literature documents CsAmerular findings in hemolytic uremic syndrome [25] . associated TMA in native kidneys of patients receiving
As shown in Figure 1 , the use of the microemulsion CsA for the treatment of diseases such as uveitis and form of CsA, Neoral, was more frequent in TMA papsoriasis [2, 5] and for nonrenal allografts [3, 9, 11, 13, tients than in patients with no graft dysfunction. Al-15]. It has been estimated that the frequency of TMA though TMA was observed also in patients on tacrolimus in bone marrow transplant recipients is between 6 and and Sandimmune, the use of Neoral was significantly 26% [23] .
more frequent among the 26 TMA patients than among The exact incidence of CsA-associated TMA in renal the 19 patients with no episodes of renal graft dysfuncgraft recipients is not known, as renal biopsy is the only tion (P ϭ 0.0026). This finding raises the possibility that available method of diagnosis of TMA, and indications Neoral, compared with the older preparation (Sandimfor renal biopsy vary among medical centers. In this mune), is more likely to cause TMA. However, use of series of renal allograft recipients treated over a threeNeoral was also more frequent among non-TMA graft year period, TMA was diagnosed in 14% (26 of 188) of dysfunction patients. Therefore, it is difficult to make a the patients, corresponding to 15% of the patients who definitive statement on the role of Neoral in contrast had a renal graft biopsy (26 of 169). At Tulane Medical to Sandimmune. The advantages of the microemulsion Center, renal graft biopsies are obtained for renal graft preparation (Neoral) over the older preparation (Sandysfunction (a rise in serum creatinine of 0.5 mg/dl or dimmune) are increased bioavailability, more predictgreater above baseline), and protocol biopsies are not able absorption, and therefore, easier dosing. On the performed. The majority of our TMA patients, 24 of 26, other hand, the pharmacokinetic behavior of Neoral is had an acute rise in serum creatinine of greater than 0.5 associated with generally rapid absorption with attainmg/dl above baseline without significant systemic sympment of higher peak drug levels in serum. It could be toms. The post-transplantation time when TMA was diproposed that this characteristic leads to an increase in agnosed in our patients (from four days to six years) had the effects of CsA on the endothelium, possibly resulting a wider range than has been previously described by in accentuated release of endothelin and other vasoactive others [7] .
products. Further understanding of the mechanisms inIn this study, only 2 of the 26 patients with TMA had volved in the endothelial cell damage by CsA [22] is systemic evidence of microangiopathy with decreased needed to develop scientific guidelines for therapeutic platelet count, increased LDH and peripheral smear reinterventions. vealing evidence of intravascular hemolysis. In the other
We investigated other parameters that could contrib-24 patients, there were no systemic clues to the diagnosis ute to TMA in our series. When patients with TMA and of TMA, except for a rise in serum creatinine. These recipients with the best evolution, that is, with no episode findings underscore the importance of considering TMA of renal graft dysfunction, were compared, the degree in the differential diagnosis of patients with renal graft of donor/recipient HLA mismatch was not different in dysfunction, even in the absence of systemic symptoms, the two groups. Furthermore, of the 35 recipients of and of performing a renal allograft biopsy to confirm living-related donor grafts, eight patients had TMA, and the diagnosis.
another eight patients had no episodes of renal graft dysfunction. In our series, TMA was observed in 7 of the CsA-associated TMA is diagnosed by renal biopsy 39 patients who received kidney and pancreas allografts native kidneys from patients receiving CsA for nonrenal allografts (solid organ grafts or bone marrow allografts) simultaneously, and in 19 out of 149 patients who received a kidney-only allograft. This difference is not staclearly demonstrates that duplication of the glomerular basement membrane and widening of the subendothelial tistically significant. An increased incidence of TMA in kidney-pancreas graft recipients has been reported beregions are frequent findings [3, [13] [14] [15] . These data are consistent with the interpretation that in renal allografts, fore [21] .
Although isometric vacuolization of the cytoplasm of these findings represent chronic CsA-effect and not rejection. the epithelium of the renal tubules, suggestive of acute CsA toxicity, was twice as frequent in the biopsies taken
In most studies of renal graft recipients, as in ours, the occurrence of de novo TMA is associated with the from patients who later had TMA episodes than in biopsies from patients with other causes of renal graft dysuse of either CsA or tacrolimus. The exception is a series of patients reported by Hourmant et al and reviewed function, this difference did not achieve statistical significance. A review of the clinical charts shows that the by Colvin as acute idiopathic microangiopathy [26, 27] . Hourmant et al reviewed 1378 patients who received CsA dosage was moderate, approximately 5 to 12 mg/kg, and no differences in CsA trough levels were observed renal allografts between 1979 and 1993 and observed TMA in 17 [26] ; the presentation of the TMA episode between the groups. The more frequent CsA tubular toxicity in biopsies of patients who later developed TMA was during the first three post-transplantation months, and none of the patients had TMA or hemolytic uremic could be related to the rapid absorption and higher peak drug levels of Neoral or represent an idiosyncratic pasyndrome before transplantation. Of the 17 patients with TMA, 13 were not on CsA at the time of the diagnosis tient response to CsA.
Thrombotic microangiopathy can be observed in the of TMA. These findings are in distinct contrast to our experience and that published by others, since all of our context of vascular and of hyperacute rejection. Severe rejection was not an important factor in our series, as TMA patients were on CsA or tacrolimus. Our preferred therapy strategy for CsA-associated simultaneous TMA and moderate or severe rejection was present in only 3 of 38 biopsies diagnostic of TMA.
TMA, in 16 of the 24 patients, was conversion from CsA to tacrolimus. The conversion strategy proved successful Interstitial fibrosis and tubular atrophy in biopsies obtained during the first 90 post-transplantation days possiin 13 of 16 patients (81%) who had a well-functioning graft one year after the TMA episode. Moreover, 11 of bly reflects donor pathology. We observed this finding more frequently in biopsies from patients with renal graft the 16 patients continued with a mean S Cr of 1.9 Ϯ 0.14 mg/dl at their last check-up 3.01 Ϯ 0.3 years (mean Ϯ dysfunction from causes different from TMA, consistent with the interpretation that interstitial fibrosis of the sem) later. Controlled prospective clinical trials in renal allograft recipients with TMA are needed to confirm the donor kidney is not related to the induction of the TMA.
A frequently associated change in kidneys showing efficacy of CsA conversion to tacrolimus in other patient populations. In view of the similarities between CsA and TMA on renal Bx, concentric proliferation of the cells of the intima and the media, with deposition of intercellular tacrolimus, it is surprising that the conversion strategy resulted in successful salvation of the grafts in a large material, is designated CsA arteriolopathy by some authors [24] . CsA-associated arteriolopathy, with cell profraction of our patients. Tacrolimus and CsA have similar mechanisms of action and side effect profiles, and TMA liferation and hyalinization of the arteriolar walls, has been described both in native kidneys of patients with can be associated with tacrolimus use, as seen in two of our patients. In previous TMA series, graft failure was nonrenal grafts and in renal allografts. In our series, the increased incidence of arteriolopathy in 38 biopsies with observed in 5 of 14 patients (36%) [22] and in 12 of 21 (57%) patients [7] . In our series, the renal graft loss in TMA was statistically significant when compared with the 67 biopsies of the 24 patients with other causes of patients with CsA-associated TMA with therapy switch from CsA to tacrolimus was 19%. renal graft dysfunction (Table 2 ). In view of this observation, the search for fibrin thrombi is mandatory in biopYoung et al obtained a 92% graft survival using a therapy regimen of pulse methylprednisolone and/or an sies with arteriolopathy. Considering the advantages of CsA therapy, there is no consensus regarding recommenantilymphocyte preparation in combination with isradipine and an antiplatelet regimen of aspirin and pentoxidations for therapy modifications in patients with arteriolopathy without TMA on renal biopsy.
fylline [21] . The difference between the experience reported by these authors and our graft salvage success Chronic transplant nephropathy [16] , with interstitial fibrosis, tubular atrophy, and thickened blood vessels, rate of 81% in patients switched from CsA to tacrolimus is not statistically significant. It is noteworthy that based was twice as frequent in biopsies taken from patients with prior episodes of TMA than in biopsies from paon serum creatinine levels, our cases appear to be milder than those reported by Young et al. Moreover, most tients with renal graft dysfunction of other etiology. The medical literature on chronic CsA-associated TMA in of their patients had systemic signs of TMA, that is, significant reductions in platelet count and hematocrit patients, TMA was confined to the kidney with little levels, in contrast to only 2 patients out of 26 in our or no systemic evidence of the thromboangiopathical series. The reverse applies when we compare the biopsy process. Therefore, we recommend that any significant findings: We observed cellular crescents in 9 of 38 biopand persistent elevation in serum of creatinine, that is, sies with TMA, whereas Young et al do not describe a greater than 0.5 mg/dl above baseline, be worked up single such case. Whether the addition of aspirin and the with a graft biopsy. In our hands, the most successful concomitant administration of either high-dose steroids intervention in patients with CsA-associated TMA was or an antilymphocyte drug confers additional benefits conversion of CsA to tacrolimus, resulting in an 81% cannot be ascertained from the comparison of these two one-year graft salvage. series and requires a controlled prospective trial. It has been suggested that complete regression of TMA can ACKNOWLEDGMENTS be obtained after stopping or reducing CsA [28] . Our 
